College of Pharmacy - Pharmacy Practice
University of Illinois, Chicago
University of California San Diego Owen Clinic
San Diego, California
Israeli Ministry of Health National Hemophilia Center at Sheba Medical Center
Tel Aviv, Israel
The educational design of this activity addresses the needs of clinical, specialty, and managed care pharmacists and pharmacy benefits managers involved in the care of patients with HIV infection.
Pharmacists play many roles in the management of HIV, thus it is essential they remain up to date as the HIV field continues to advance and patients grow more complex. This activity discusses the importance of and strategies for rapid antiretroviral therapy (ART) initiation, the indications for and implementation of long-acting injectable ART, the interpretation of resistance testing, and the complex therapeutic decision-making processes involved in designing active ART regimens for heavily treatment-experienced patients with HIV.
After completing this activity, the participant should be better able to:
- Review requirements and options for rapid ART initiation
- Identify the pharmacist’s role within clinic protocols for common HIV management scenarios, such as initiating rapid ART and implementing long-acting injectables
- Describe procedures for long-acting injectable treatment initiation and maintenance
- Interpret resistance test results in HTE patients with multidrug resistance
- Discuss the most appropriate treatment regimens for HTE patients experiencing virologic failure or those who want to simplify their regimen
Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with commendation.
Global Education Group designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-23-053-H02-P)
This is an application-based activity.
Global Education Group Contact Information
For information about the accreditation of this program, please contact Global Education Group at 303-395-1782 or email@example.com.
Instructions to Receive Credit
In order to received credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Preactivity Questions.
- Review the activity content.
- Achieve a grade of 70% on the Postactivity Test Questions and complete the Evaluation.
- CE credits will be uplaoded to CPE Monitor within 60 days of completion.
Fee Information& Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months to Global Education Group. All financial relationships reported are identified as relevant and mitigated by Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global Education Group to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Melissa Badowski, PharmD: Nothing to disclose.
Lucas Hill, PharmD: Gilead Science, ViiV Healthcare
Jonathan M. Schapiro, MD: Consulting Fee (eg, Advisory Board): Gilead Sciences, GlaxoSmithKline, Merck, Moderna, Pfizer, Tibotec-Janssen, Teva, ViiV Healthcare; Honoraria: Gilead Sciences, GlaxoSmithKline, Merck, Moderna, Pfizer, Tibotec-Janssen, Teva Viiv Healthcare
The planners and managers at Global Education Group and Integritas Communications have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.